Article
Chemistry, Medicinal
Huifang Shan, Xinyu Ma, Guoyi Yan, Meng Luo, Xinxin Zhong, Suke Lan, Jie Yang, Yuanyuan Liu, Chunlan Pu, Yu Tong, Rui Li
Summary: A series of covalent CDK4/6 inhibitors were designed and synthesized, with compound C-13 showing potent anticancer activity in vitro and significant tumor growth inhibition in a mouse model.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Cell Biology
Navid Sobhani, Anne Fassl, Giuseppina Mondani, Daniele Generali, Tobias Otto
Summary: Breast cancer is the leading cause of cancer-related death in women globally, and therapies targeting molecular pathways like CDK4/6 inhibitors have significantly improved treatment options. Although CDK4/6 inhibitors have shown promising efficacy in hormone receptor-positive, HER2-negative breast cancer, resistance mechanisms, particularly involving the FGFR pathway, have been observed in some patients.
Review
Biochemistry & Molecular Biology
Erin R. Scheidemann, Ayesha N. Shajahan-Haq
Summary: ER+ breast cancer is the most common form, with resistance to antiestrogens leading to the development of CDK4/6 inhibitors as a successful alternative treatment option. However, resistance to these inhibitors is also common, with various mechanisms identified. Future research should focus on developing biomarkers to guide treatment strategies for resistant patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Mattia Garutti, Giada Targato, Silvia Buriolla, Lorenza Palmero, Alessandro Marco Minisini, Fabio Puglisi
Summary: Historically, metastatic melanoma was considered highly lethal, but recent drug developments have improved prognosis significantly. The use of BRAF/MEK inhibitors and anti-PD1 antibodies has revolutionized disease management. However, not all patients benefit from these therapies, leading to the need for new clinically active compounds to be tested in clinical trials.
Review
Oncology
Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander
Summary: CDK4/6 inhibitors have become the standard of care for patients with hormone receptor-positive advanced breast cancer. Research efforts have identified common resistance drivers and precision-guided therapeutic strategies are under development.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Braso-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Odena, Monica Sanchez-Guixe, Marta Capelan, Analia Azaro, Alejandra Bruna, Olga Rodriguez, Marta Guzman, Judit Grueso, Cristina Viaplana, Javier Hernandez, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquin Arribas, Stefan Michiels, Alicia Garcia-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Summary: CDK4/6 inhibitors combined with endocrine therapy show higher antitumor activity in the treatment of estrogen receptor-positive breast cancer. Overexpression of p16 is associated with reduced effectiveness of CDK4/6 inhibitors, while heterozygous RB1 loss is a biomarker of acquired resistance and poor clinical outcome. Combination of CDK4/6 inhibitor ribociclib with PI3K inhibitor alpelisib demonstrates antitumor activity regardless of specific mutations, even without endocrine therapy.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Eva Quandt, Nuria Masip, Sara Hernandez-Ortega, Abril Sanchez-Botet, Laura Gasa, Ainhoa Fernandez-Elorduy, Sara Plutta, Joan Marc Martinez-Lainez, Samuel Bru, Pau M. Munoz-Torres, Martin Floor, Jordi Villa-Freixa, May C. Morris, August Vidal, Alberto Villanueva, Josep Clotet, Mariana P. C. Ribeiro
Summary: Through yeast two-hybrid screening, we identified 10 new atypical cyclin-CDK complexes, including an active complex between CDK6 and cyclin I (CCNI) against retinoblastoma protein. Upregulation of CCNI increased breast cancer cell proliferation in vitro and in vivo, similar to the effect of cyclin D upregulation, but this effect was abolished by CDK6 silencing or palbociclib treatment. CCNI downregulation led to a decrease in cell number and a reduction in the percentage of cells reaching S phase. CCNI upregulation was also associated with high expression of E2F target genes in cancer cell lines and breast cancer tissue samples.
MOLECULAR ONCOLOGY
(2023)
Article
Medicine, General & Internal
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David A. Cameron
Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
Summary: CDK 4/6 inhibitors are a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. This article reviews the clinical pharmacokinetic and pharmacodynamic profiles of these inhibitors and discusses important future directions for their clinical applicability.
Article
Oncology
Mohammadhadi Khorrami, Vidya Sakar Viswanathan, Priyanka Reddy, Nathaniel Braman, Siddharth Kunte, Amit Gupta, Jame Abraham, Alberto J. Montero, Anant Madabhushi
Summary: Imaging texture biomarkers before and after CDK4/6i therapy can predict early response and overall survival in MBC patients with liver metastases. Radiomic features can predict a lack of response earlier than standard anatomic/RECIST 1.1 assessment, highlighting the need for further study and clinical validation.
Article
Medicine, Research & Experimental
Aparna Padhye, Jessica M. Konen, B. Leticia Rodriguez, Jared J. Fradette, Joshua K. Ochieng, Lixia Diao, Jing Wang, Wei Lu, Luisa S. Solis, Harsh Batra, Maria G. Raso, Michael D. Peoples, Rosalba Minelli, Alessandro Carugo, Christopher A. Bristow, Don L. Gibbons
Summary: This work received support from multiple sources including the National Institutes of Health, the Cancer Prevention & Research Institute of Texas, the University of Texas, and generous philanthropic contributions. The Flow Cytometry Lab at MD Anderson Cancer Center is supported by a Cancer Center Support Grant.
Article
Multidisciplinary Sciences
Wei Zhou, Wenxi Wang, Yuxin Liang, Ruibin Jiang, Fensheng Qiu, Xiying Shao, Yang Liu, Le Fang, Maowei Ni, Chenhuan Yu, Yue Zhao, Weijia Huang, Jiong Li, Michael J. Donovan, Lina Wang, Juan Ni, Dachi Wang, Ting Fu, Jianguo Feng, Xiaojia Wang, Weihong Tan, Xiaohong Fang
Summary: The study reveals that the RNA binding protein LRPPRC forms a positive feedback loop with CDK6, and inhibiting LRPPRC overcomes CDK4/6 inhibition resistance. This research uncovers the mechanism of CDK4/6i resistance and provides a novel approach to combine CDK4/6 and LRPPRC inhibitors for cancer therapy.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Colt Egelston, Weihua Guo, Susan Yost, Jin Sun Lee, David Rose, Christian Avalos, Jian Ye, Paul Frankel, Daniel Schmolze, James Waisman, Peter Lee, Yuan Yuan
Summary: This study highlights that patients with HR+ MBC treated with a combination of CDK4/6 inhibitor and ICI show increased frequencies of effector memory CD8+ and CD4+ T cells in their peripheral blood, which may serve as potential biomarkers of clinical response. Additionally, changes in myeloid cell composition were observed in patients receiving the combination therapy, indicating a dynamic modulation of the immune system in response to treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ran Sun, Xuemei Wang, Leichao Zhang, Yu Gu, Shaojuan Yang, Liping Wang, Xueju Wang
Summary: CDK6 protein expression in urothelial carcinoma can be used as a screening platform for CDK4/6 inhibitor targeted therapy.
FRONTIERS IN ONCOLOGY
(2022)
